Neuropathogenesis of HIV-associated neurocognitive disorders: Roles for immune activation, HIV blipping and viral tropism

Current Opinion in HIV and AIDS

Volumn 9, Issue 6, 2014, Pages 559-564

  Chen, Maria F ^a   Gill, Alexander J ^a   Kolson, Dennis L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

brain; HIV; HIV blip; HIV associated neurocognitive disorder; Inflammation; Viral blip

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRAL TROPISM; VIRUS REPLICATION; VIRUS STRAIN; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

CENTRAL NERVOUS SYSTEM DISEASES; COGNITION DISORDERS; HIV INFECTIONS; HIV-1; HUMANS; VIRAL TROPISM;

EID: 84912024901     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000105     Document Type: Review

References (35)

1. Manji H, Jager HR, Winston A. HIV, dementia and antiretroviral drugs: 30 years of an epidemic. J Neurol Neurosurg Psychiatry 2013; 84:1126-1137.
2. Price RW, Spudich SS, Peterson J, et al. Evolving character of chronic central nervous system HIV infection. Semin Neurol 2014; 34:7-13.
3. Canizares S, Cherner M, Ellis RJ. HIV and aging: effects on the central nervous system. Semin Neurol 2014; 34:27-34.
4. Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis 2013; 13:976-986.
5. Gill AJ, Kolson DL. Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV/AIDS Rep 2014; 11:325-335.
6. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012; 206:275-282.
7. Burdo TH, Lackner A, Williams KC. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev 2013; 254:102-113.
8. Uzasci L, Nath A, Cotter R. Oxidative stress and the HIV-infected brain proteome. J Neuroimmune Pharmacol 2013; 8:1167-1180.
9. Childers ME, Woods SP, Letendre S, et al. Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. J Neurovirol 2008; 14:550-557.
10. Monteiro de Almeida S, Letendre S, Zimmerman J, et al. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol 2005; 169:144-152.
11. Gisslen M, Rosengren L, Hagberg L, et al. Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. AIDS Res Ther 2005; 2:6.
12. Stam AJ, Nijhuis M, van den Bergh WM, Wensing AM. Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review. AIDS Rev 2013; 15:152-161.
13. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev 2013; 26:2-18.
14. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013; 21:6-13.
15. Valcour VG, Ananworanich J, Agsalda M, et al. HIVDNA reservoir increases risk for cognitive disorders in cART-naive patients. PLoS One 2013; 8:e70164.
16. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014; 10:e1003829.
17. Wang Y, Kasper LH. The role of microbiome in central nervous system disorders. Brain Behav Immun 2014; 38:1-12.
18. Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 2012; 205:1230-1238.
19. Murray JM, Zaunders JJ, Koelsch KK, et al. Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting. AIDS Res Hum Retroviruses 2013; 29:1621-1625.
20. Castro P, Plana M, Gonzalez R, et al. Influence of episodes of intermittent viremia ('blips') on immune responses and viral load rebound in successfully treated HIV-infected patients. AIDS Res Hum Retroviruses 2013; 29:68-76.
21. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-778.
22. Benmarzouk-Hidalgo OJ, Torres-Cornejo A, Gutierrez-Valencia A, et al. Immune activation throughout a boosted darunavir monotherapy simplification strategy. Clin Microbiol Infect 2013. [Epub ahead of print]
23. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202:1819-1825.
24. Khoury MN, Tan CS, Peaslee M, Koralnik IJ. CSF viral escape in a patient with HIV-associated neurocognitive disorder. J Neurovirol 2013; 19:402-405.
25. Zoufaly A, Kiepe J, Hertling S, et al. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals. HIV Med 2014. [Epub ahead of print]
26. Taiwo B, Bosch RJ. More reasons to reexamine the definition of viral blip during antiretroviral therapy. J Infect Dis 2012; 205:1189-1191.
27. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243-1250.
28. Eden A, Andersson L, Fuchs D, et al. Cerebrospinal fluid viral blips and persistent escape in HIV-infected patients on ART. Conference on Retroviruses and Opportunistic Infections [Abstract #445]. Topics Antiviral Med 2014; 22:210.
29. Pozniak A, Gupta RK, Pillay D, et al. Causes and consequences of incomplete HIV RNA suppression in clinical trials. HIV Clin Trials 2009; 10:289-298.
30. Nightingale S, Group PS. HIV-1 RNA detection in CSF in ART-treated subjects with incomplete viral suppression in plasma. Conference on Retroviruses and Opportunistic Infections [Abstract #442]. Topics Antiviral Med 2014; 22:209.
31. Pozniak A, Gupta RK, Pillay D, et al. Causes and consequences of incomplete HIV RNA suppression in clinical trials. HIV Clin Trials 2009; 10:289-298.
32. Nightingale S, Group PS. HIV-1 RNA detection in CSF in ART-treated subjects with incomplete viral suppression in plasma. Conference on Retroviruses and Opportunistic Infections [Abstract #442]. Topics Antiviral Med 2014; 22:209.
33. Schnell G, Joseph S, Spudich S, et al. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog 2011; 7:e1002286.
34. Joseph SB, Arrildt KT, Swanstrom AE, et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol 2014; 88:1858-1869.
35. Sturdevant CB, Dow A, Jabara CB, et al. Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children. PLoS Pathog 2012; 8:e1003094.